These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29523589)

  • 1. Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure.
    Nadruz W; Gioli-Pereira L; Bernardez-Pereira S; Marcondes-Braga FG; Fernandes-Silva MM; Silvestre OM; Sposito AC; Ribeiro AL; Bacal F; Fernandes F; Krieger JE; Mansur AJ; Pereira AC
    Heart; 2018 Sep; 104(18):1522-1528. PubMed ID: 29523589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease.
    Freitas HF; Chizzola PR; Paes AT; Lima AC; Mansur AJ
    Int J Cardiol; 2005 Jul; 102(2):239-47. PubMed ID: 15982491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different prognostic impact of the tissue Doppler-derived E/e' ratio on mortality in Chagas cardiomyopathy patients with heart failure.
    Nunes MP; Colosimo EA; Reis RC; Barbosa MM; da Silva JL; Barbosa F; Botoni FA; Ribeiro AL; Rocha MO
    J Heart Lung Transplant; 2012 Jun; 31(6):634-41. PubMed ID: 22305956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
    Shen L; Ramires F; Martinez F; Bodanese LC; Echeverría LE; Gómez EA; Abraham WT; Dickstein K; Køber L; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Jhund PS; Gimpelewicz CR; McMurray JJV;
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum brain-derived neurotrophic factor levels in patients with Chagas cardiomyopathy.
    Costa HS; Lima MMO; Figueiredo PHS; Martinelli PM; Camargos ER; Chaves AT; Nunes MCP; Rocha MOC
    Mem Inst Oswaldo Cruz; 2018 Aug; 113(10):e180224. PubMed ID: 30133549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why do patients with chagasic cardiomyopathy have worse outcomes than those with non-chagasic cardiomyopathy?
    Silva CP; Del Carlo CH; Oliveira Junior MT; Scipioni A; Strunz-Cassaro C; Ramirez JA; Pereira Barretto AC
    Arq Bras Cardiol; 2008 Dec; 91(6):358-62. PubMed ID: 19142362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
    Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification of mortality in patients with heart failure and left ventricular ejection fraction >35%.
    Cygankiewicz I; Zareba W; Vazquez R; Bayes-Genis A; Pascual D; Macaya C; Almendral J; Fiol M; Bardaji A; Gonzalez-Juanatey JR; Nieto V; Valdes M; Cinca J; de Luna AB;
    Am J Cardiol; 2009 Apr; 103(7):1003-10. PubMed ID: 19327431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of heart failure prognostic factors in patients referred for heart transplantation.
    Areosa CM; Almeida DR; Carvalho AC; Paola AA
    Arq Bras Cardiol; 2007 Jun; 88(6):667-73. PubMed ID: 17664994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure.
    Lee SE; Lee HY; Cho HJ; Choe WS; Kim H; Choi JO; Jeon ES; Kim MS; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Cho MC; Kim JJ; Oh BH
    JACC Heart Fail; 2017 Nov; 5(11):810-819. PubMed ID: 29096790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends in long-term mortality of patients with acute heart failure: Data from 1985-2008.
    van den Berge JC; Akkerhuis MK; Constantinescu AA; Kors JA; van Domburg RT; Deckers JW
    Int J Cardiol; 2016 Dec; 224():456-460. PubMed ID: 27723568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors in Severe Chagasic Heart Failure.
    Costa SA; Rassi S; Freitas EMDM; Gutierrez NDS; Boaventura FM; Sampaio LPDC; Silva JBM
    Arq Bras Cardiol; 2017 Mar; 108(3):246-254. PubMed ID: 28443956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]).
    Cherian TS; Shrader P; Fonarow GC; Allen LA; Piccini JP; Peterson ED; Thomas L; Kowey PR; Gersh BJ; Mahaffey KW
    Am J Cardiol; 2017 Jun; 119(11):1763-1769. PubMed ID: 28416199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Chagas cardiomyopathy an independent risk factor for patients with heart failure?
    Braga JC; Reis F; Aras R; Dantas N; Bitencourt A; Neves FS; Latado AL
    Int J Cardiol; 2008 May; 126(2):276-8. PubMed ID: 17467084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
    Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
    Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.